Entera Bio Ltd. Depreciation & Amortization

Depreciation & Amortization of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Depreciation & Amortization growth rates and interactive chart.


Highlights and Quick Summary

  • Depreciation & Amortization for the quarter ending June 29, 2020 was $51 Thousand (a 2.0% increase compared to previous quarter)
  • Year-over-year quarterly Depreciation & Amortization decreased by -19.05%
  • Annual Depreciation & Amortization for 2019 was $238 Thousand (a 340.74% increase from previous year)
  • Annual Depreciation & Amortization for 2018 was $54 Thousand (a 25.58% increase from previous year)
  • Twelve month Depreciation & Amortization ending June 29, 2020 was $217 Thousand (a -6.47% decrease compared to previous quarter)
  • Twelve month trailing Depreciation & Amortization increased by 7.43% year-over-year
Trailing Depreciation & Amortization for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$217 Thousand $232 Thousand $238 Thousand $202 Thousand
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Depreciation & Amortization of Entera Bio Ltd.

Most recent Depreciation & Amortizationof ENTX including historical data for past 10 years.

Interactive Chart of Depreciation & Amortization of Entera Bio Ltd.

Entera Bio Ltd. Depreciation & Amortization for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $0.05 $0.05
2019 $0.05 $0.06 $0.07 $0.06 $0.24
2018 $0.02 $0.01 $0.01 $0.02 $0.05
2017 $0.04 $0.04

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.